Search
Healthy Group Announces: Livzon Pharmaceutical Secures Approval for Clinical Trial of YJH-012 Injection
2 day ago /
Read about 0 minute
Author：小编
Healthy Group's subsidiary, Livzon Pharmaceutical, has recently obtained approval from the National Medical Products Administration (NMPA) to initiate clinical trials for its innovative siRNA drug, YJH-012 Injection. This groundbreaking therapy is anticipated to offer prolonged inhibition of uric acid production at the genetic level. To date, Livzon Pharmaceutical has invested approximately RMB 25.7386 million in the research and development of YJH-012 Injection. Given the inherent uncertainties associated with drug development, the progress and outcomes of the clinical trials remain to be seen. Healthy Group commits to promptly disclosing relevant information as required.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
